

Drug Monograph

Drug/Drug **Loprox[®] (ciclopirox olamine) suspension/ Topical**
 Class: **Antifungals**
 Prepared for: MO HealthNet
 Prepared by: Conduent

New Criteria

Revision of Existing Criteria

Executive Summary

Purpose: The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.

Dosage Forms: Loprox[®] is now available in a topical suspension containing 0.55% ciclopirox olamine.

Manufacturer: Teligent Pharma, Inc., Buena, NJ 08310

Indications: Loprox[®] topical suspension is indicated for the topical treatment of the following dermal infections: tinea pedis, tinea cruris, and tinea corporis due to *Trichophyton rubrum*, *Trichophyton mentagrophytes*, *Epidermophyton floccosum*, and *Microsporum canis*; cutaneous candidiasis due to *Candida albicans*; and tinea versicolor due to *Malassezia furfur*.

Costs: \$254.18 per kit of Loprox[®] topical suspension . Wholesale Acquisition Cost

Summary of Findings: This drug is being considered for inclusion in the state specific Preferred Drug List.

Status Recommendation:

<input type="checkbox"/> Prior Authorization (PA) Required	<input type="checkbox"/> Open Access
<input type="checkbox"/> Fiscal Edit	<input checked="" type="checkbox"/> PDL

Type of PA Criteria:

<input type="checkbox"/> Increased Risk of ADE	<input checked="" type="checkbox"/> Under Solicitation
<input type="checkbox"/> Appropriate Indications	<input type="checkbox"/> Non Preferred

Prepared By: Luke Boehmer Pharm.D.
 Date: March 10, 2017